We are live on ! Find out more
AMRN icon

Amarin Corp

12.11 USD
-0.63
4.95%
At close Updated Oct 30, 4:00 PM EDT
1 day
-4.95%
5 days
0.58%
1 month
-6.85%
3 months
-14.9%
6 months
-13.07%
Year to date
-11.73%
1 year
-26.16%
5 years
-87.46%
10 years
-80.59%
 

About: Amarin Corp PLC is a pharmaceutical company. The company is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa. The company focuses on treatments to stop cardiovascular disease causing death, by providing patients, doctors and investors with reliable cardiovascular treatment options. Geographically, the company derives maximum revenue from United States.

Employees: 80

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 30%
Neutral 70%
Negative 0%
Positive
Zacks Investment Research
3 days ago
Amarin's Q3 Earnings Beat Estimates, Revenues Miss Mark
AMRN's Q3 2026 earnings surpass estimates despite declining revenues. Global Vascepa/Vazkepa demand grows 55% and cash reserves increase.
Amarin's Q3 Earnings Beat Estimates, Revenues Miss Mark
Neutral
Seeking Alpha
3 days ago
Amarin Corporation plc (AMRN) Q3 2026 Earnings Call Transcript
Amarin Corporation plc (AMRN) Q3 2026 Earnings Call Transcript
Amarin Corporation plc (AMRN) Q3 2026 Earnings Call Transcript
Positive
MarketBeat
4 days ago
What Amarin (AMRN) Said on Its Q3 Earnings Call
Amarin NASDAQ: AMRN reported its first profitable quarter in two years for the third quarter of 2026, as lower operating expenses, positive operating cash flow and growth in international in-market demand helped offset continued U.S. pricing pressure for its VASCEPA cardiovascular therapy.
What Amarin (AMRN) Said on Its Q3 Earnings Call
Neutral
GlobeNewsWire
4 days ago
Amarin Reports 2026 Third Quarter Financial Results, Achieves Positive Net Income
DUBLIN and BRIDGEWATER, N.J., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular disease worldwide, today announced financial results for the third quarter ended September 30, 2026 (Q3 2026) highlighting profitable third quarter results, strong momentum in its fully partnered international business strategy and continued U.S. market share leadership.
Amarin Reports 2026 Third Quarter Financial Results, Achieves Positive Net Income
Neutral
GlobeNewsWire
7 days ago
Amarin Provides Update on University of Leeds Sponsored Phase 3 EPA for Metastasis Trial 2 (EMT2) Evaluating VAZKEPA®/VASCEPA® (icosapent ethyl) Capsules on Top of Standard of Care Treatment in Patients Undergoing Liver Resection for Colorectal Cancer Liver Metastases (CRCLM)
Pre-specified and Statistically Powered Key Endpoints Included Progression-free Survival (PFS) and Overall Survival (OS). Although Primary Endpoint of PFS Was Not Met, The   Key Secondary Endpoint of OS Was Improved With VAZKEPA/VASCEPA
Amarin Provides Update on University of Leeds Sponsored Phase 3 EPA for Metastasis Trial 2 (EMT2) Evaluating VAZKEPA®/VASCEPA® (icosapent ethyl) Capsules on Top of Standard of Care Treatment in Patients Undergoing Liver Resection for Colorectal Cancer Liver Metastases (CRCLM)
Neutral
GlobeNewsWire
11 days ago
Amarin to Report Third Quarter 2026 Financial Results and Host Conference Call on October 28, 2026
DUBLIN and BRIDGEWATER, N.J., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company advancing the science of cardiovascular therapeutics worldwide, today announced that it will report third quarter 2026 financial results and conduct a conference call on Wednesday, October 28, 2026.
Amarin to Report Third Quarter 2026 Financial Results and Host Conference Call on October 28, 2026
Positive
Zacks Investment Research
1 month ago
Is Amarin (AMRN) Stock Outpacing Its Medical Peers This Year?
Here is how Amarin (AMRN) and Royalty Pharma (RPRX) have performed compared to their sector so far this year.
Is Amarin (AMRN) Stock Outpacing Its Medical Peers This Year?
Neutral
GlobeNewsWire
2 months ago
Amarin Highlights New REDUCE-IT® and Mechanistic Data Presented at European Society of Cardiology (ESC) Congress 2026
Presentations Expand Understanding of Treatment Adherence, Long-Term Outcomes, Lipoprotein(a), Coagulation Biomarkers, and Potential Mechanisms of Eicosapentaenoic Acid (EPA)
Amarin Highlights New REDUCE-IT® and Mechanistic Data Presented at European Society of Cardiology (ESC) Congress 2026
Neutral
GlobeNewsWire
2 months ago
New REDUCE-IT® Legacy Analysis Presented at European Society of Cardiology (ESC) Congress 2026 Suggests Persistent Cardiovascular Benefit Following Icosapent Ethyl Treatment Cessation in Adherent Patients
DUBLIN and BRIDGEWATER, N.J., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular disease worldwide, today highlighted a new post hoc analysis from the landmark REDUCE-IT® cardiovascular outcomes trial, presented at the European Society of Cardiology (ESC) Congress 2026 in Munich, Germany.
New REDUCE-IT® Legacy Analysis Presented at European Society of Cardiology (ESC) Congress 2026 Suggests Persistent Cardiovascular Benefit Following Icosapent Ethyl Treatment Cessation in Adherent Patients
Neutral
GlobeNewsWire
2 months ago
New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2026
DUBLIN and BRIDGEWATER, N.J., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular disease worldwide, today announced upcoming presentations at the European Society of Cardiology (ESC) Congress 2026, August 28t h - 31st, in Munich, Germany.
New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2026
Price charts implemented using Lightweight Charts™